Clinical trial NCT06066710: Propranolol in Primary Progressive Aphasia
Official title: Trial of Propranolol in Older Adults with Primary Progressive Aphasia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Aphasia, Primary Progressive
Lead sponsor: University of Missouri-Columbia
Sponsor class: OTHER
First posted: 2023-10-04
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.

This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.


Eligibility criteria: Inclusion Criteria:

* 1. Age: 50 and older
* 2. Primary Progressive Aphasia diagnosis
* 3. Native English speaker

Exclusion Criteria:

* 1. Unable to provide consent
* 2. Taking alpha 2 agonists (clonidine and guanfacine)
* 3. Other major psychological or neurological diagnosis
* 4. Major head trauma that contributed to their condition
* 5. Allergic reaction to adhesives
* 6. Uncorrected vision/hearing impairments
* 7. Diabetes
* 8. Reactive airway disease
* 9. Untreated hypothyroidism
* 10. Bradyarrhythmia
* 11. Unexplained syncope
* 12. Pregnancy (assessed verbally on the days of MR imaging)
* 13. Drugs that interact with propranolol, such as alpha 2 agonists
* 14. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.

Primary outcomes:
measure: Change in Neuropsychological Assessment Battery Naming Test
timeFrame: Day 1, 4 Weeks, 8 Weeks, 10 Weeks, 14 Weeks,18 Weeks
Secondary outcomes:
measure: Change in State-Trait Anxiety Inventory for Adults
timeFrame: Day 1, 4 Weeks, 8 Weeks, 10 Weeks,14 Weeks,18 Weeks
measure: Change in Semantic Word Fluency Tasks
timeFrame: Day 1, 8 Weeks,18 Weeks
Other outcomes:
Locations:
city: Columbia
country: United States
facility: University of Missouri-Columbia
state: Missouri
Study officials:
affiliation: University of Missouri-Columbia
name: David Beversdorf, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001 Apr;49(4):425-32.
citation: Mesulam M, Weintraub S. Primary progressive aphasia and kindred disorders. Handb Clin Neurol. 2008;89:573-87. doi: 10.1016/S0072-9752(07)01254-7. No abstract available.
citation: Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. Classification of primary progressive aphasia and its variants. Neurology. 2011 Mar 15;76(11):1006-14. doi: 10.1212/WNL.0b013e31821103e6. Epub 2011 Feb 16.
citation: Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, Chute DJ, Roberson ED, Pace-Savitsky C, Neumann M, Chow TW, Rosen HJ, Forstl H, Kurz A, Miller BL. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005 Jun;62(6):925-30. doi: 10.1001/archneur.62.6.925.
citation: Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol. 2010 Feb;6(2):88-97. doi: 10.1038/nrneurol.2009.216.
citation: Albert ML, Bachman DL, Morgan A, Helm-Estabrooks N. Pharmacotherapy for aphasia. Neurology. 1988 Jun;38(6):877-9. doi: 10.1212/wnl.38.6.877.
citation: Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, Lai J, Unwin DH. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001 Sep;32(9):2093-8. doi: 10.1161/hs0901.095720.
citation: Beversdorf DQ. Pharmacotherapy of aphasia. J Head Trauma Rehabil. 2007 Jan-Feb;22(1):65-6. doi: 10.1097/00001199-200701000-00008. No abstract available.
citation: Zamzow RM, Ferguson BJ, Stichter JP, Porges EC, Ragsdale AS, Lewis ML, Beversdorf DQ. Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study. Psychopharmacology (Berl). 2016 Apr;233(7):1171-8. doi: 10.1007/s00213-015-4199-0. Epub 2016 Jan 14.
citation: Beversdorf DQ, Sharma UK, Phillips NN, Notestine MA, Slivka AP, Friedman NM, Schneider SL, Nagaraja HN, Hillier A. Effect of propranolol on naming in chronic Broca's aphasia with anomia. Neurocase. 2007 Aug;13(4):256-9. doi: 10.1080/13554790701595471.
citation: Faigel HC. The effect of beta blockade on stress-induced cognitive dysfunction in adolescents. Clin Pediatr (Phila). 1991 Jul;30(7):441-5. doi: 10.1177/000992289103000706.
citation: Laverdure B, Boulenger JP. [Beta-blocking drugs and anxiety. A proven therapeutic value]. Encephale. 1991 Sep-Oct;17(5):481-92. French.
citation: Cahana-Amitay D, Albert ML, Pyun SB, Westwood A, Jenkins T, Wolford S, Finley M. Language as a Stressor in Aphasia. Aphasiology. 2011;25(2):593-614. doi: 10.1080/02687038.2010.541469. Epub 2011 Apr 19.